Dillon, Kasia M.
Bekele, Raie T.
Sztupinszki, Zsofia
Hanlon, Timothy
Rafiei, Shahrzad
Szallasi, Zoltan
Choudhury, Atish D. http://orcid.org/0000-0001-9344-6631
Mouw, Kent W. http://orcid.org/0000-0001-7939-7343
Funding for this research was provided by:
Prostate Cancer Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA219504)
U.S. Department of Defense (PC190196, CA228696, PC190196)
U.S. Department of Health & Human Services | National Institutes of Health (W81XWH-18-2-0056)
Kræftens Bekæmpelse
Article History
Received: 17 September 2021
Accepted: 8 June 2022
First Online: 29 June 2022
Competing interests
: K.W.M.: Pfizer, EMD Serono, UroGen (advisor/consulting); Pfizer (research support to institution); UpToDate (writing/editor fees); OncLive (speaking fees); institutional patent files on mutational signatures of DNA repair deficiency. A.C.: Clovis, Dendreon, Bayer, Eli Lilly, Blackstone, AstraZeneca (advisory/consulting); Bayer (research funding). Z.S.: listed as an inventor on a patent used in the MyChoice HRD assay with royalties paid. The remaining authors declare no competing interests.